The for specialty injectable generics is rapidly growing as patent exclusivities expire on many blockbuster biologic drugs. Specialty biologics like Humira, which generated over $20 billion in global sales in 2021, are expected to come off patent in the next 5-10 years. This presents a major opportunity for generic manufacturers to introduce biosimilar versions at a fraction of the c... https://zippy-goat-z7kvvr.mystrikingly.com/blog/the-growing-role-of-specialty-injectable-generics-inhealthcare